ABOUT PAREXEL INTERNATIONAL
Parexel is a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 22,000+ global employees work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart®. We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships. For more information, visit parexel.com and follow us on LinkedIn, X, Facebook and Instagram.
SOLUTIONS
CONTACT INFORMATION
Parexel International
541 Church at North Hills St., Suite 1000
Raleigh, NC 27609
UNITED STATES
INDUSTRY INSIGHTS
-
![Woman checking in at a site reception desk 1 (high res)]( "Creating Shared Value For Patients And Payers In Retinal Gene Therapies")
Retinal gene therapies must balance clinical outcomes, patient needs, and payer expectations. Learn how developers can align value, access, and reimbursement to deliver meaningful patient impact.
-
![APAC - elderly man helped by home care worker outdoors (high res)]( "Designing Wet AMD Gene Therapies: Strategies That Drive Success")
Gene therapy offers new hope for retinal diseases like wet AMD. Learn the key clinical, regulatory, and operational priorities for advancing retinal gene therapies.
-
![HCP speaking with a patient in an exam room (high res) (1)]( "FDA's Plausible Mechanism Pathway For Personalized Gene Therapies")
As personalized gene therapies emerge, FDA’s plausible‑mechanism pathway offers a faster route to approval. Learn how this new framework could reshape development strategies and accelerate breakthrough therapies.
-
![EU - elderly woman with walker and HCP on sidewalk (high res)]( "Navigating FDA's CMC Expectations For Cell And Gene Therapy")
As FDA updates CMC expectations for cell and gene therapies, developers must address critical quality, consistency, and safety requirements. Learn how strategic manufacturing choices can speed and strengthen development.
-
![Doctor and nurse having a conversation about a patients chart (high res)]( "Unlocking CAR‑T Success With Essential FDA Guidance Insights")
CAR‑T therapies promise breakthrough impact but come with tough clinical and regulatory demands. Get the key FDA guidance sponsors need to navigate complexity and accelerate these transformative programs.
-
![Female patient consults with an HCP during in-home visit (high res)]( "5 Strategies For Designing Successful Complex Rare Disease Trials")
Rare disease trials demand inventive design. Uncover creative strategies that help sponsors overcome tiny populations, complex endpoints, and operational hurdles to advance meaningful breakthroughs.
-
![Elderly woman at home with HCP using stethoscope 1 (high res)]( "Biotech's Next Wave: Breakthroughs Fueling Innovation And Investment")
Biotech is shifting fast as scientific advances spark new investment and development models. Learn how emerging trends are propelling next‑generation therapies at record speed.
